Sun Pharmaceutical Industries Ltd. has received Covenant Not to Sue from Wyeth over Sun Pharma’s Abbreviated New Drug Application (ANDA) for an antidepressant.

Sun Pharmaceutical has received  Covenant Not to Sue from Wyeth over Sun Pharma’s Abbreviated New Drug Application (ANDA) for generic venlafaxine extended release tablets with multiple para IV certifications. This ANDA for generic venlafaxine extended release tablets, AB-rated equivalent of Wyeth’s Effexor XR® Capsules,  includes three strengths: 37.5 mg, 75 mg and 150 mg and is based on innovative technology for extended release  tablets. These strengths of Effexor XR® Capsules have annual sales of approximately USD 2.6 billion in the US.

Wyeth covenants not to sue Sun under any claims of US Patent Nos. 6,274,171, 6,4013,120 and 6,419,958. Venlafaxine is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class. Effexor XR ® is a registered trademark of Wyeth Pharmaceuticals Inc